Investment in Associate (Tables)

12 Months Ended

Dec. 31, 2023

VISEN Pharmaceuticals [member]

Disclosure of associates [line items]

Schedule of Financial Information of Investment in VISEN

The following table illustrates the summarized relevant financial information of VISEN:

	VISEN Pharmaceuticals
Principal place of business	China
	2023			2022
	(EUR’000)
Statement of profit or (loss)
Profit/(loss) for the year from continuing operations		(41,873	)		(40,283	)
Total comprehensive income		(41,859	)		(40,273	)
Statement of financial position
Non-current assets		9,596			21,410
Current assets		48,041			92,204
Total assets		57,637			113,614
Equity		51,078			100,062
Non-current liabilities		140			180
Current liabilities		6,419			13,372
Total equity and liabilities		57,637			113,614
Company’s share of equity before eliminations		22,438			43,957
Elimination of internal profit and other equity method adjustments		(16,752	)		(21,025	)
Company’s share of equity		5,686			22,932
Investment in associate at December 31		5,686			22,932
Present ownership at December 31		43.93	%		43.93	%
Transactions and outstanding balances as of December 31
Invoicing of goods and services to associate		15,026			22,327
Trade receivables from associate		991			3,554
Contract liabilities		7,133			14,213